Shares of Sun Pharmaceutical Industries jumped on Monday after the company announced an $11.75 billion acquisition of Organon & Co, marking one of the largest outbound deals by an Indian pharmaceutical firm.
The stock was trading around Rs 1,739.70 as of 9:46 am, up over 7%, after touching a high of Rs 1,741.85 during the session, reflecting strong investor interest following the announcement.
, valuing the US-based company at about $11.75 billion, including debt. The company will buy all outstanding shares at $14 per share, offering a premium of more than 24% over Organon’s last closing price.
Organon, which was spun off from Merck & Co. in 2021, carries a debt of $8.6 billion. It reported a 5% fall in quarterly revenue and a net loss of $205 million, indicating operational challenges that Sun Pharma will look to address post-acquisition.
The rally in Sun Pharma’s stock is largely driven by the strategic value of the deal.
The acquisition gives the company access to:
This significantly expands Sun Pharma’s global footprint and diversifies its product mix.
Dilip Shanghvi, Executive Chairman of Sun Pharma, said the deal would strengthen the company’s platform.
“Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organisations together can create a stronger and more diversified platform,” he said.
Sun Pharma has been focusing on specialty therapies such as dermatology, oncology and obesity treatment. The acquisition of Organon allows it to expand into new areas like biosimilars and strengthen its innovative medicines portfolio.
The move also helps the company reduce its dependence on the US generics market, where pricing pressure and policy changes under President Donald Trump have impacted margins.
Among Indian pharma companies, Sun Pharma has one of the highest exposures to the US market. The deal is seen as a step towards balancing that exposure by strengthening its global presence.
Sun Pharma plans to fund the acquisition through a mix of internal cash reserves and committed financing from banks.
Despite the large deal size, investors appear to be comfortable with the funding strategy and the long-term growth potential.
The market reaction suggests that investors view the deal as a long-term positive for Sun Pharma.
The acquisition not only adds scale but also positions the company in high-growth segments like women’s health and specialty medicines.
Going ahead, the key factor will be how effectively Sun Pharma integrates Organon and delivers value from this acquisition.